Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

AbbVie stock

ABBV
US00287Y1091
A1J84E

Price

173.21
Today +/-
+5.17
Today %
+3.19 %

AbbVie stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AbbVie stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AbbVie stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AbbVie stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AbbVie's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AbbVie Stock Price History

DateAbbVie Price
11/21/2024173.21 undefined
11/20/2024167.76 undefined
11/19/2024166.57 undefined
11/18/2024166.28 undefined
11/15/2024164.99 undefined
11/14/2024169.63 undefined
11/13/2024171.38 undefined
11/12/2024171.09 undefined
11/11/2024174.43 undefined
11/8/2024199.50 undefined
11/7/2024200.51 undefined
11/6/2024201.20 undefined
11/5/2024201.68 undefined
11/4/2024200.47 undefined
11/1/2024203.55 undefined
10/31/2024203.87 undefined
10/30/2024201.50 undefined
10/29/2024189.45 undefined
10/28/2024189.68 undefined
10/25/2024187.85 undefined
10/24/2024189.65 undefined
10/23/2024187.88 undefined

AbbVie Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AbbVie, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AbbVie from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AbbVie’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AbbVie. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AbbVie’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AbbVie’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AbbVie’s growth potential.

AbbVie Revenue, EBIT and net profit per share

DateAbbVie RevenueAbbVie EBITAbbVie Net Income
2029e74.63 B undefined0 undefined31.28 B undefined
2028e71.83 B undefined36.61 B undefined28.82 B undefined
2027e67.6 B undefined33.83 B undefined26.41 B undefined
2026e64.96 B undefined31.13 B undefined24.67 B undefined
2025e60.42 B undefined28.29 B undefined21.87 B undefined
2024e57.18 B undefined25.38 B undefined19.72 B undefined
202354.32 B undefined16.55 B undefined4.82 B undefined
202258.05 B undefined20.12 B undefined11.78 B undefined
202156.2 B undefined19.47 B undefined11.47 B undefined
202045.8 B undefined13.07 B undefined4.56 B undefined
201933.27 B undefined13.32 B undefined7.84 B undefined
201832.75 B undefined12.07 B undefined5.66 B undefined
201728.22 B undefined9.8 B undefined5.28 B undefined
201625.64 B undefined9.6 B undefined5.92 B undefined
201522.86 B undefined7.87 B undefined5.14 B undefined
201419.96 B undefined3.76 B undefined1.77 B undefined
201318.79 B undefined6.02 B undefined4.13 B undefined
201218.38 B undefined6.3 B undefined5.28 B undefined
201117.44 B undefined4.5 B undefined3.43 B undefined
201015.64 B undefined5.18 B undefined4.18 B undefined
200914.21 B undefined5.13 B undefined4.64 B undefined

AbbVie Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
2009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
14.2115.6417.4418.3818.7919.9622.8625.6428.2232.7533.2745.856.258.0554.3257.1860.4264.9667.671.8374.63
-10.0211.555.372.236.2314.5212.1610.0616.081.5737.6922.693.30-6.445.275.657.524.066.253.91
71.4672.5973.6475.4775.6277.8380.3177.3274.6376.9377.1466.6969.1971.5366.4563.1259.7455.5653.3950.2548.36
10.1611.3512.8513.8714.2115.5318.3619.8221.0625.225.6630.5538.8841.5336.09000000
4.644.183.435.284.131.775.145.925.285.667.844.5611.4711.784.8219.7221.8724.6726.4128.8231.28
--9.90-17.8353.66-21.74-57.03189.9715.14-10.817.0838.62-41.90151.712.74-59.09309.2110.8612.847.029.168.52
---------------------
---------------------
1.581.581.581.581.61.611.641.631.61.551.481.671.781.781.77000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The AbbVie Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AbbVie is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20102011201220132014201520162017201820192020202120222023
                           
0.010.657.989.98.378.416.429.798.0639.928.489.839.2312.82
3.373.824.33.853.744.734.765.095.385.438.829.9811.2511.16
0009490000000000
0.840.871.091.151.121.721.441.611.611.813.313.133.584.1
42.011.9922.851.463.564.741.92.353.564.994.44.93
8.227.3515.3517.8516.0816.3116.1921.2216.9549.5224.1727.9328.4633
2.362.142.252.32.492.572.62.82.883.316.145.875.675.73
0.140.230.120.120.090.151.782.091.420.090.290.280.240.3
00000000000000
3.692.912.321.891.5119.7128.927.5621.2318.6582.8875.9567.4455.61
6.26.16.136.285.8613.1715.4215.7915.6615.633.1232.3832.1632.29
0.530.780.840.771.481.151.211.331.211.943.964.124.837.77
12.9212.1711.6511.3511.4336.7449.9149.5642.4139.6126.39118.6110.34101.71
21.1319.5227.0129.227.5153.0566.170.7959.3589.12150.57146.53138.81134.71
                           
0001616171818181818181818
0003.674.1913.0813.6814.2714.7615.1917.3818.3119.2520.18
0001.570.542.254.385.463.374.721.063.134.78-1
15.711.913.36-0.44-2.03-2.61-2.63-2.73-2.47-3.6-3.12-2.9-2.2-2.31
02602047460-1000000
15.711.933.364.812.7112.7815.4917.0215.6616.3315.3418.5521.8516.89
0.363.915.736.386.894.534.785.15.574.588.799.94910.32
3.41.970002.993.533.834.735.429.0310.2212.2515.6
0000.070.060.951.071.291.631.832.342.544.154.74
001.020.410.430.410.380.43.700.030.0100
00.020.020.024.012.030.036.021.613.758.4712.484.147.19
3.765.96.786.8811.3910.899.7816.6417.2415.5928.6635.1929.5437.84
00.0314.6314.2910.5429.2436.4430.953562.9877.5564.1959.1452.19
00000.165.286.892.491.071.133.653.012.191.95
1.671.662.243.543.683.78.3515.6114.4917.627.6128.730.6632.33
1.671.6916.8717.8314.3838.2151.6849.0550.5681.7108.8195.991.9886.47
5.437.5923.6524.7125.7749.1161.4665.6967.897.29137.47131.09121.52124.31
21.1319.5227.0129.5228.4961.8976.9582.7183.46113.62152.81149.64143.37141.21
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AbbVie provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AbbVie's financial health and stability.

Assets

AbbVie's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AbbVie must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AbbVie after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AbbVie's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200920102011201220132014201520162017201820192020202120222023
4.644.183.435.284.131.775.145.955.315.697.884.6211.5511.854.87
0.71.181.271.150.90.790.841.191.51.772.026.478.528.478.7
00000000000-2,325-898-1,931-2,889
0.5-0.870.71-0.620.66-0.790.5-1.690.01-1.13-1.330.11-1.32-0.262.81
-0.310.6510.730.82.021.331.943.517.525.189.475.627.4910.09
00000.280.420.540.991.11.221.792.622.712.552.47
00001.310.51.113.561.70.041.451.673.652.994.7
5.374.986.256.356.273.557.547.049.9613.4313.3217.5922.7824.9422.84
-312-448-355-333-491-612-532-479-529-638-552-798-787-695-777
-486-5,031553-2,418879-926-12,936-6,074-274-1,006596-37,557-2,344-623-2,009
-0.17-4.580.91-2.091.37-0.31-12.4-5.60.26-0.371.15-36.76-1.560.07-1.23
000000000000000
-0.03-0.03-0.0215.59-0.60.0116.625.59-03.2326.25-2.68-8.41-12.43-4.15
000027-427-7,425-5,765-1,156-11,941-621-769-690-1,225-1,792
-4.880.07-6.781.93-3.44-3.295.75-3.93-5.51-14.418.71-11.5-19.04-24.8-17.22
-4,84697-6,761-13,655-313-217-152-34-246-104-552-333-674-1,102-742
0000-2,555-2,661-3,294-3,717-4,107-5,580-6,366-7,716-9,261-10,043-10,539
00.010.025.873.69-1.250.05-3.34.2-2.0132.64-31.481.3-0.553.61
5,054.774,528.025,891.456,0125,7762,9377,0036,5629,43112,78912,77216,79021,99024,24822,062
000000000000000

AbbVie stock margins

The AbbVie margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AbbVie. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AbbVie.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AbbVie's sales revenue. A higher gross margin percentage indicates that the AbbVie retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AbbVie's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AbbVie's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AbbVie's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AbbVie. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AbbVie's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AbbVie Margin History

AbbVie Gross marginAbbVie Profit marginAbbVie EBIT marginAbbVie Profit margin
2029e66.45 %0 %41.91 %
2028e66.45 %50.98 %40.13 %
2027e66.45 %50.05 %39.06 %
2026e66.45 %47.92 %37.98 %
2025e66.45 %46.82 %36.2 %
2024e66.45 %44.39 %34.49 %
202366.45 %30.47 %8.87 %
202271.53 %34.66 %20.29 %
202169.19 %34.65 %20.41 %
202066.69 %28.53 %9.95 %
201977.14 %40.04 %23.57 %
201876.93 %36.85 %17.27 %
201774.63 %34.74 %18.72 %
201677.32 %37.46 %23.1 %
201580.31 %34.43 %22.5 %
201477.83 %18.85 %8.89 %
201375.62 %32.02 %21.97 %
201275.47 %34.28 %28.7 %
201173.64 %25.79 %19.68 %
201072.59 %33.11 %26.72 %
200971.46 %36.08 %32.62 %

AbbVie Stock Sales Revenue, EBIT, Earnings per Share

The AbbVie earnings per share therefore indicates how much revenue AbbVie has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AbbVie earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AbbVie's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AbbVie’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AbbVie's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AbbVie Revenue, EBIT and net profit per share

DateAbbVie Sales per ShareAbbVie EBIT per shareAbbVie Earnings per Share
2029e42.23 undefined0 undefined17.7 undefined
2028e40.64 undefined0 undefined16.31 undefined
2027e38.25 undefined0 undefined14.94 undefined
2026e36.76 undefined0 undefined13.96 undefined
2025e34.19 undefined0 undefined12.37 undefined
2024e32.36 undefined0 undefined11.16 undefined
202330.64 undefined9.34 undefined2.72 undefined
202232.65 undefined11.32 undefined6.63 undefined
202131.62 undefined10.96 undefined6.45 undefined
202027.38 undefined7.81 undefined2.72 undefined
201922.42 undefined8.98 undefined5.28 undefined
201821.19 undefined7.81 undefined3.66 undefined
201717.6 undefined6.11 undefined3.3 undefined
201615.72 undefined5.89 undefined3.63 undefined
201513.96 undefined4.81 undefined3.14 undefined
201412.4 undefined2.34 undefined1.1 undefined
201311.71 undefined3.75 undefined2.57 undefined
201211.66 undefined4 undefined3.34 undefined
201111.04 undefined2.85 undefined2.17 undefined
20109.89 undefined3.27 undefined2.64 undefined
20098.99 undefined3.24 undefined2.93 undefined

AbbVie business model

Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie is one of the most popular companies on Eulerpool.com.

AbbVie SWOT Analysis

Strengths

Abbvie Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a strong portfolio of patented drugs, providing a competitive advantage and ensuring a steady revenue stream. Additionally, Abbvie has a robust research and development (R&D) pipeline, constantly working on innovative therapies and treatments. This allows the company to stay ahead of competitors and meet the evolving needs of patients.

Weaknesses

Despite its strengths, Abbvie Inc faces certain weaknesses that could hinder its growth. One significant weakness is its heavy dependence on a few key drugs for a significant portion of its revenue. This makes the company vulnerable to patent expirations and the entry of generic competitors. Furthermore, Abbvie has limited international market presence compared to some of its competitors, which reduces its global reach and potential market share.

Opportunities

There are several opportunities that Abbvie Inc can capitalize on to drive future growth. Expanding into emerging markets such as China and India presents significant potential as these markets are experiencing rapid economic growth and an increasing demand for quality healthcare. Moreover, Abbvie can explore strategic partnerships or acquisitions to diversify its product portfolio and gain access to new markets or technologies. Additionally, the growing focus on personalized medicine opens avenues for the company to develop targeted therapies and further differentiate itself.

Threats

Abbvie Inc faces certain threats that could impact its performance and market position. One major threat is the increasing competition in the pharmaceutical industry, both from established players and new entrants. This intensifies pricing pressures and requires Abbvie to continuously innovate and differentiate its offerings. Additionally, regulatory and political uncertainties, such as changes in healthcare policies or drug pricing regulations, pose risks to the company's operations and profitability.

AbbVie Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AbbVie Revenue by Segment

Segmente2022202120202019201820172016201520142013
Humira21.24 B USD---------
Skyrizi-2.94 B USD1.59 B USD-------
SKYRIZI---355 M USD------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AbbVie Revenue by Segment

Segmente2022202120202019201820172016201520142013
HUMIRA---19.17 B USD-18.43 B USD16.08 B USD--10.66 B USD
Humira-20.69 B USD19.83 B USD-------
Represents information pertaining to HUMIRA, a product of the entity-------14.01 B USD12.54 B USD-
All other4.14 B USD-2.92 B USD511 M USD319 M USD998 M USD1.22 B USD---
Imbruvica4.57 B USD-5.31 B USD-------
IMBRUVICA---4.67 B USD-2.57 B USD1.83 B USD---
Creon1.28 B USD-1.11 B USD1.04 B USD-831 M USD730 M USD--412 M USD
Skyrizi5.17 B USD---------
Botox Therapeutic2.72 B USD-1.39 B USD-------
Lupron--752 M USD887 M USD-829 M USD821 M USD--785 M USD
Botox Cosmetic2.62 B USD-1.11 B USD-------
Synthroid--771 M USD786 M USD-781 M USD763 M USD--622 M USD
Mavyret1.54 B USD-1.83 B USD-------
Venclexta2.01 B USD-1.34 B USD-------
Rinvoq2.52 B USD-731 M USD-------
Synagis---718 M USD-738 M USD730 M USD--827 M USD
Vraylar2.04 B USD-951 M USD-------
MAVYRET---2.89 B USD------
Represents information pertaining to other products of the entity not specified anywhere-------1.22 B USD1.63 B USD-
Represents information pertaining to AndroGel, a product of the entity-------694 M USD934 M USD1.04 B USD
Represents information pertaining to Kaletra, a product of the entity-------700 M USD870 M USD962 M USD
Duodopa458 M USD-494 M USD461 M USD-355 M USD293 M USD--178 M USD
Juvederm Collection1.43 B USD-718 M USD-------
Other Aesthetics1.29 B USD-760 M USD-------
Other Eye Care1.18 B USD-693 M USD-------
Sevoflurane---348 M USD-410 M USD428 M USD--568 M USD
Linzess/Constella1.04 B USD-667 M USD-------
Represents information pertaining to VIEKIRA, a product of the entity-------1.64 B USD48 M USD-
Other Products---------1.67 B USD
Represents information pertaining to Lupron, a product of the entity-------826 M USD778 M USD-
Represents information pertaining to Synagis, a product of the entity-------740 M USD835 M USD-
VIEKIRA---36 M USD--1.52 B USD---
Represents information pertaining to Synthroid, a product of the entity-------755 M USD709 M USD-
Restasis666 M USD-787 M USD-------
AndroGel---172 M USD-577 M USD675 M USD---
HCV-----1.27 B USD----
Kaletra---283 M USD-423 M USD549 M USD---
Represents information pertaining to Creon, a product of the entity-------632 M USD516 M USD-
Dyslipidemia Products---------1.08 B USD
Represents information pertaining to Sevoflurane, a product of the entity-------474 M USD550 M USD-
Other Neuroscience475 M USD-539 M USD-------
Lumigan/Ganfort514 M USD-378 M USD-------
Ubrelvy680 M USD-125 M USD-------
VENCLEXTA---792 M USD------
Represents information pertaining to Imbruvica, a product of the entity-------754 M USD--
Alphagan/Combigan346 M USD-326 M USD-------
Represents information pertaining to dyslipidemia products of the entity-------179 M USD328 M USD-
Represents information pertaining to Duodopa, a product of the entity-------231 M USD220 M USD-
Lo Loestrin--356 M USD-------
Other Women's Health--192 M USD-------
Qulipta158 M USD---------
Orilissa/Oriahnn--125 M USD-------
ORILISSA---93 M USD------
RINVOQ---47 M USD------

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AbbVie Revenue by Segment

Segmente2022202120202019201820172016201520142013
Imbruvica-5.41 B USD--------
All other-2.67 B USD--------
Botox Therapeutic-2.45 B USD--------
Botox Cosmetic-2.23 B USD--------
Venclexta-1.82 B USD--------
Vraylar-1.73 B USD--------
Mavyret-1.71 B USD--------
Rinvoq-1.65 B USD--------
Juvederm Collection-1.54 B USD--------
Other Aesthetics-1.47 B USD--------
Restasis-1.29 B USD--------
Creon-1.19 B USD--------
Other Eye Care-1.17 B USD--------
Linzess/Constella-1.04 B USD--------
Lupron-783 M USD--------
Synthroid-767 M USD--------
Other Neuroscience-685 M USD--------
Lumigan/Ganfort-579 M USD--------
Ubrelvy-552 M USD--------
Alphagan/Combigan-529 M USD--------
Duodopa-511 M USD--------
Lo Loestrin-437 M USD--------
Other Women's Health-214 M USD--------
Orilissa/Oriahnn-145 M USD--------

AbbVie Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

AbbVie Revenue by Segment

DateAll other countriesAustraliaB [R]BrazilBRAZILC [A]CanadaChinaD [E]E [S]F [R]FranceG [B]GermanyI [T]ItalyJ [P]JapanN [L]Other CountriesRepresents information pertaining to other countries not specified anywhereSpainThe NetherlandsU [S]United KingdomUnited States
20224.84 B USD508 M USD-430 M USD--1.16 B USD912 M USD---787 M USD-1.34 B USD-444 M USD-956 M USD---506 M USD--462 M USD45.71 B USD
20214.76 B USD533 M USD-368 M USD--1.4 B USD857 M USD---936 M USD-1.22 B USD-506 M USD-1.09 B USD---519 M USD--497 M USD43.51 B USD
20203.98 B USD527 M USD-406 M USD--1.16 B USD471 M USD---797 M USD-1.05 B USD-379 M USD-1.2 B USD---453 M USD--509 M USD34.88 B USD
20193.99 B USD--359 M USD--813 M USD----695 M USD-909 M USD-372 M USD-1.21 B USD---472 M USD163 M USD-372 M USD23.91 B USD
20184.01 B USD--350 M USD--730 M USD----783 M USD-1.29 B USD-652 M USD-1.59 B USD---611 M USD352 M USD-855 M USD21.52 B USD
20174.08 B USD--410 M USD--659 M USD----730 M USD-1.16 B USD-475 M USD-764 M USD---521 M USD362 M USD-807 M USD18.25 B USD
20163.89 B USD--355 M USD--624 M USD----713 M USD-1.1 B USD-523 M USD-770 M USD---589 M USD352 M USD-776 M USD15.95 B USD
2015--376 M USD--551 M USD--1.08 B USD618 M USD597 M USD-688 M USD-452 M USD-599 M USD-334 M USD-4 B USD--13.56 B USD--
2014--435 M USD--551 M USD--1.04 B USD534 M USD584 M USD-722 M USD-432 M USD-581 M USD-969 M USD-3.27 B USD--10.85 B USD--
2013----439 M USD-538 M USD----540 M USD-911 M USD-404 M USD-625 M USD-3.15 B USD-543 M USD858 M USD-606 M USD10.18 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AbbVie Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AbbVie historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AbbVie shares outstanding

The number of shares was AbbVie in 2023 — This indicates how many shares 1.773 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AbbVie earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AbbVie's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AbbVie’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AbbVie's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AbbVie dividend history and estimates

In 2023, AbbVie paid a dividend amounting to 5.92 USD. Dividend means that AbbVie distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for AbbVie provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify AbbVie’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating AbbVie's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

AbbVie Dividend History

DateAbbVie Dividend
2029e5.97 undefined
2028e5.99 undefined
2027e6.04 undefined
2026e5.88 undefined
2025e6.04 undefined
2024e6.21 undefined
20235.92 undefined
20225.64 undefined
20215.2 undefined
20204.72 undefined
20194.28 undefined
20183.59 undefined
20172.56 undefined
20162.28 undefined
20152.02 undefined
20141.66 undefined
20131.6 undefined

AbbVie dividend payout ratio

In 2023, AbbVie had a payout ratio of 113.07%. The payout ratio indicates the percentage of the company's profits that AbbVie distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for AbbVie represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for AbbVie could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate AbbVie's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

AbbVie Payout Ratio History

DateAbbVie Payout ratio
2029e98.77 %
2028e98.34 %
2027e96.98 %
2026e101 %
2025e97.02 %
2024e92.92 %
2023113.07 %
202285.07 %
202180.62 %
2020173.53 %
201981.06 %
201898.36 %
201777.81 %
201662.81 %
201564.33 %
2014150.91 %
201362.26 %
2012113.07 %
2011113.07 %
2010113.07 %
2009113.07 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for AbbVie.

AbbVie latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20242.97 3  (0.9 %)2024 Q3
6/30/20242.62 2.65  (1.28 %)2024 Q2
3/31/20242.27 2.31  (1.73 %)2024 Q1
12/31/20232.82 2.79  (-1.14 %)2023 Q4
9/30/20232.91 2.95  (1.23 %)2023 Q3
6/30/20232.86 2.91  (1.65 %)2023 Q2
3/31/20232.51 2.46  (-1.85 %)2023 Q1
12/31/20223.63 3.6  (-0.83 %)2022 Q4
9/30/20223.64 3.66  (0.42 %)2022 Q3
6/30/20223.38 3.37  (-0.31 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the AbbVie stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

62

👫 Social

91

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
342,607
Scope 2 - Indirect emissions from purchased energy
271,055
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
613,662
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56
Percentage of women in management
Percentage of Asian employees18
Share of Asian management23
Percentage of Hispanic/Latino employees9
Hispano/Latino Management share6
Percentage of Black employees7
Black Management Share5
Percentage of white employees62
White Management Share62
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AbbVie shareholders

%
Name
Stocks
Change
Date
9.61423 % The Vanguard Group, Inc.169,896,974272,6896/30/2024
5.05916 % BlackRock Institutional Trust Company, N.A.89,402,376-3,397,0686/30/2024
4.40261 % State Street Global Advisors (US)77,800,250-170,4086/30/2024
2.18444 % Capital International Investors38,602,184-9,496,6006/30/2024
2.07577 % Geode Capital Management, L.L.C.36,681,750-812,9036/30/2024
1.89694 % JP Morgan Asset Management33,521,6241,327,6366/30/2024
1.87792 % Capital Research Global Investors33,185,3941,890,2446/30/2024
1.41328 % Charles Schwab Investment Management, Inc.24,974,5772,257,2636/30/2024
1.27203 % Norges Bank Investment Management (NBIM)22,478,4651,636,4426/30/2024
1.11276 % Morgan Stanley Smith Barney LLC19,663,978990,9596/30/2024
1
2
3
4
5
...
10

AbbVie Executives and Management Board

Mr. Richard Gonzalez(69)
AbbVie Chairman of the Board, Chief Executive Officer (since 2013)
Compensation 26.29 M
Mr. Robert Michael(52)
AbbVie President, Chief Operating Officer (since 2017)
Compensation 9.77 M
Mr. Jeffrey Stewart(54)
AbbVie Executive Vice President, Chief Commercial Officer
Compensation 9.63 M
Dr. Azita Saleki Gerhardt(59)
AbbVie Executive Vice President - Operations
Compensation 9 M
Mr. Scott Reents(55)
AbbVie Chief Financial Officer, Executive Vice President
Compensation 5.62 M
1
2
3
4
...
5

AbbVie Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Asymchem Laboratories (Tianjin) H Stock
Asymchem Laboratories (Tianjin) H
SupplierCustomer0,800,85-0,16
Berkshire Hathaway B Stock
Berkshire Hathaway B
SupplierCustomer0,740,820,880,950,960,90
Molecular Partners AG Stock
Molecular Partners AG
SupplierCustomer0,730,800,470,24-0,30
NNIT Stock
NNIT
SupplierCustomer0,710,760,19-0,65-0,81-0,68
Evolus, Inc. Stock
Evolus, Inc.
SupplierCustomer0,68-0,260,280,850,340,55
Model N Stock
Model N
SupplierCustomer0,630,790,44-0,50-0,80-0,77
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Stock
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
SupplierCustomer0,620,65
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,560,150,710,800,640,80
Pfizer Stock
Pfizer
SupplierCustomer0,560,810,79-0,280,600,81
Innodata Stock
Innodata
SupplierCustomer0,510,460,530,52-0,430,44
1
2
3
4
5
...
6

Most common questions regarding AbbVie

What values and corporate philosophy does AbbVie represent?

Abbvie Inc represents values of innovation, integrity, and a patient-centric approach. With a corporate philosophy focused on discovering and delivering advanced solutions, Abbvie strives to make a remarkable impact on people's lives. The company is committed to advancing science and developing breakthrough treatments in various therapeutic areas, including immunology, oncology, and neuroscience. Abbvie's dedication to excellence and its emphasis on collaboration and ethical practices enable the company to provide transformative healthcare solutions for patients worldwide.

In which countries and regions is AbbVie primarily present?

Abbvie Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with a focus on key markets such as the United States, Europe, Asia Pacific, and Latin America. Abbvie Inc operates in multiple countries, including the United Kingdom, Germany, France, Italy, Japan, China, Australia, Brazil, and Mexico, among others. With their international reach, Abbvie Inc continues to expand its business operations and leverage opportunities in different markets to serve a diverse customer base.

What significant milestones has the company AbbVie achieved?

Abbvie Inc, a leading pharmaceutical company, has achieved several significant milestones. In 2013, the company was spun off from Abbott Laboratories, marking a significant step towards establishing its independent identity. Abbvie has also made remarkable progress in the development of innovative therapies. Notably, their drug Humira became a game-changer, becoming the world's best-selling medicine and achieving several regulatory approvals for multiple indications. In addition, Abbvie has expanded its pipeline with the successful launch of new products like Skyrizi and Rinvoq, further strengthening its position in the industry. These accomplishments highlight Abbvie Inc's commitment to advancing healthcare and improving patient outcomes.

What is the history and background of the company AbbVie?

Abbvie Inc is a pharmaceutical company with a rich history and background. It was established in 2013 as a spin-off from Abbott Laboratories. Abbvie focuses on researching, developing, and manufacturing innovative drugs to address various health conditions. With headquarters in North Chicago, Illinois, Abbvie operates on a global scale, delivering advanced therapies to patients worldwide. The company is renowned for its expertise in immunology, oncology, neuroscience, and virology areas. Abbvie has a diverse portfolio of products, including popular brands such as Humira, Imbruvica, and Venclexta, which have positively impacted millions of lives. With a commitment to advancing science and improving patient outcomes, Abbvie continues to make significant contributions to the healthcare industry.

Who are the main competitors of AbbVie in the market?

The main competitors of Abbvie Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Bristol-Myers Squibb Company.

In which industries is AbbVie primarily active?

Abbvie Inc is primarily active in the pharmaceutical industry.

What is the business model of AbbVie?

The business model of Abbvie Inc is focused on research, development, and commercialization of innovative pharmaceutical products. Abbvie specializes in the discovery and production of drugs primarily in the fields of immunology, oncology, and neuroscience. The company aims to provide effective therapies for various medical conditions, improving the quality of life for patients worldwide. With a strong focus on research and development, Abbvie strives to bring new treatments to market and address unmet medical needs. Through strategic partnerships and collaborations, Abbvie ensures a diversified product portfolio and maintains its position as a leading pharmaceutical company.

What is the P/E ratio of AbbVie 2024?

The AbbVie P/E ratio is 15.57.

What is the P/S ratio of AbbVie 2024?

The AbbVie P/S ratio is 5.37.

What is the Quality Investing of AbbVie?

The Quality Investing for AbbVie is 10/10.

What is the revenue of AbbVie 2024?

The expected AbbVie revenue is 57.18 B USD.

How high is the profit of AbbVie 2024?

The expected AbbVie profit is 19.72 B USD.

What is the business model of AbbVie

Abbvie Inc. is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for some of the world's most serious diseases. This primarily includes oncology, immunological disorders, neurodegenerative diseases, skin diseases, viral and bacterial infections, eye diseases, and metabolic disorders. Abbvie has been an independent company since 2013, following a spin-off from Abbott Laboratories. The company is headquartered in North Chicago, Illinois, USA, and employs over 30,000 people worldwide. Abbvie has four main business segments: 1. Immunology: Approximately 60 percent of Abbvie's revenue comes from the immunology division. The company specializes in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis. Key products in the immunology division include Humira, Rinvoq, SkyRizi, and Skyrizi. 2. Hematology and Oncology: Abbvie also has a strong presence in the field of hematology and oncology. Leading products in this segment include Venclexta, Imbruvica, and Mavyret. 3. Neurology: Abbvie also offers products in the field of neurology, such as Skyrizi, Botox, Azelex, and Tazorac. 4. Aesthetic Medicine: The company offers products like Juvederm and Botox in this segment. Abbvie invests heavily in research and development to discover innovative therapies that can improve the lives of patients worldwide. The company has a strong portfolio of patents and prioritizes comprehensive clinical testing in the development of new products to ensure high quality and efficacy. Additionally, the company has formed several collaborative partnerships to accelerate its research and development in various areas. For example, Abbvie has partnered with Biogen in the development of drugs for multiple sclerosis and has cooperated with Alector in the field of neurodegenerative diseases. Abbvie continues to delight its customers with valuable products and services, thereby expanding its leading position in the biopharmaceutical industry. In summary, Abbvie is an innovative and rapidly growing company that plays an important role in the global biopharmaceutical market through its top-notch products and investments in research and development.

What is the AbbVie dividend?

AbbVie pays a dividend of 5.64 USD distributed over 4 payouts per year.

How often does AbbVie pay dividends?

AbbVie pays out a dividend 4 times a year.

What is the AbbVie ISIN?

The ISIN of AbbVie is US00287Y1091.

What is the AbbVie WKN?

The WKN of AbbVie is A1J84E.

What is the AbbVie ticker?

The ticker of AbbVie is ABBV.

How much dividend does AbbVie pay?

Over the past 12 months, AbbVie paid a dividend of 5.92 USD . This corresponds to a dividend yield of about 3.42 %. For the coming 12 months, AbbVie is expected to pay a dividend of 6.04 USD.

What is the dividend yield of AbbVie?

The current dividend yield of AbbVie is 3.42 %.

When does AbbVie pay dividends?

AbbVie pays a quarterly dividend. This is distributed in the months of May, August, November, February.

How secure is the dividend of AbbVie?

AbbVie paid dividends every year for the past 101 years.

What is the dividend of AbbVie?

For the upcoming 12 months, dividends amounting to 6.04 USD are expected. This corresponds to a dividend yield of 3.6 %.

In which sector is AbbVie located?

AbbVie is assigned to the 'Health' sector.

Wann musste ich die Aktien von AbbVie kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AbbVie from 11/15/2024 amounting to 1.55 USD, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.

When did AbbVie pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of AbbVie in the year 2023?

In the year 2023, AbbVie distributed 5.64 USD as dividends.

In which currency does AbbVie pay out the dividend?

The dividends of AbbVie are distributed in USD.

All fundamentals about AbbVie

Our stock analysis for AbbVie Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AbbVie Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.